Close Menu

NEW YORK – Boston-based NanoView Biosciences has signed an exclusive agreement with Isaza Scientific to distribute Nanoview's ExoView platform in Spain and Portugal.

The research-use-only ExoView platform is an antibody labeling and imaging-based extracellular vesicle detection tool that provides high-resolution sizing, counting, and phenotyping. NanoView said that the platform requires minimal sample input, no sample prep or purification, and can be used directly with complex biological samples.

To read the full story....

...and receive Daily News bulletins.

Already have a GenomeWeb or 360Dx account?
Login Now.

Don't have a GenomeWeb or 360Dx account?
Register for Free.

The US Food and Drug Administration is to announce stricter standards for emergency authorizations of SARS-CoV-2 vaccines, reports the Washington Post.

The Associated Press reports Johnson & Johnson is starting a late-stage clinical trial of its candidate SARS-CoV-2 vaccine.

Bloomberg reports the budget of Operation Warp Speed is actually $18 billion, higher than the number typically cited.

In Genome Research this week: genomic analysis reveals role of super-spreaders in SARS-CoV-2, epigenetic drivers of cancer, and more.